Multimeric NKG2D Decoys for High-Avidity Ligand Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NKG2D-based cancer immunotherapy approaches face challenges due to moderate affinity for ligands and the requirement for homodimer formation, leading to high dosing needs for effective binding of shed ligands in circulation, which can be prohibitively high.
Innovation Solution
Development of NKG2D decoys comprising at least two monomers to form a functioning homodimer, potentially multimerized and glycosylated, to enhance binding affinity and avidity for NKG2DL, allowing for effective neutralization of both cell-bound and soluble ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If monomeric chimeric constructs are used to target NKG2D ligands, then the construct design is simpler, but the binding affinity and avidity are insufficient leading to prohibitively high dosing requirements
Solution Approach 1:
The patent merges multiple NKG2D monomers into a single multimeric construct (e.g., trimers, tetramers, or higher order oligomers) to create a decoy molecule that can simultaneously bind multiple ligands. This combining approach increases binding avidity without requiring multiple separate monomeric constructs, thereby reducing the dosing requirement while maintaining manageable construct design complexity through modular assembly strategies.
2Reliability
If NKG2D must form a homodimer to bind ligands effectively, then the binding specificity is improved, but the dosing requirement increases due to the need for at least two monomeric constructs
Solution Approach 1:
The patent combines multiple NKG2D monomers into pre-assembled multimeric decoys that inherently possess the homodimeric or higher-order structure required for specific ligand binding. This approach ensures binding specificity is maintained while eliminating the need to administer multiple separate monomeric constructs, thereby reducing dosing requirements.
Solution Approach 2:
The patent performs preliminary assembly of NKG2D monomers into multimeric structures with correct stoichiometry and orientation before administration. This pre-assembly ensures that the decoys are ready to bind ligands with high specificity immediately upon contact, eliminating the need for in-vivo dimer formation and reducing the dosing requirement.
3Adaptability or versatility
If multiple monomeric chimeric constructs are administered to achieve effective binding, then the binding coverage is improved, but the dosing requirement becomes prohibitively high
Solution Approach 1:
The patent merges multiple binding sites into a single multimeric decoy construct, where each monomer unit contributes a ligand-binding interface. This creates a versatile molecule that can bind multiple different NKG2D ligands simultaneously, achieving broad binding coverage with a single construct type and thereby eliminating the need for high dosing of multiple separate constructs.
Solution Approach 2:
The patent designs multimeric decoys with universal binding capability across multiple NKG2D ligand types (e.g., MICA, MICB, ULBP family members). The multimeric structure provides multiple identical or distinct binding sites that can recognize different ligands, making the single construct type universally effective against various tumor-associated ligands and eliminating the need for multiple specialized monomeric constructs.
Data Source
AI summary
Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.